Gateway Health Alliances has announced the publication of updated clinical results showing that its patented botanical extracts, Dyglomera (Dichrostachys glomerata) and CQR-300 (Cissus quadrangularis), significantly increased natural GLP-1 levels by inhibiting DPP-4 activity.
Published in the peer-reviewed journal Medicina, the 16-week clinical trial used 248 overweight and obese adults taking Gateway ingredients (300 mg Dyglomera or 400 mg CQR-300 daily).
The findings showed subjects experienced meaningful weight loss, improved body composition and enhanced markers of metabolic health, without prescribed dietary restriction, compared to placebo.
The study is among the larger human studies evaluating standardised botanical extracts for GLP-1/DPP-4 outcomes.
Key findings include the following:
- Increased active GLP-1 levels: at week 16, 3-hour postprandial active GLP-1 increased by +38.6 pg/mL (+294.7%) with Dyglomera and +42.2 pg/mL (+321.4%) with CQR-300, compared to +4.7 pg/mL (+36.1%) with placebo
- Inhibited DPP-4 enzyme activity: DPP-4 activity decreased by 15.3% with Dyglomera and 17.8% with CQR-300, versus a 2.9% reduction in the placebo group, supporting increased endogenous GLP-1 availability
- Clinically meaningful weight and body-fat reduction: participants experienced average body-weight reductions of 5.2% (Dyglomera) and 5.8% (CQR-300), alongside body-fat reductions of 10.3% and 10.9%, respectively, compared with 0.7% weight loss and 1.5% fat loss in the placebo group
- Reduced calorie intake and enhanced satiety: daily energy intake decreased by 16.2% (Dyglomera) and 17.5% (CQR-300) versus 3.1% with placebo, while subjective satiety scores increased by 25.6% and 27.4%, respectively, compared to 5.3% with placebo
- Improved metabolic biomarkers. Both botanical extracts significantly reduced fasting glucose, triglycerides and total cholesterol. Changes in LDL-C and HDL-C were modest and did not reach statistical significance.
"This expanded trial demonstrates the consistency and strength of our science," said Shil Kothari, President of Gateway Health Alliances.
"Dyglomera and CQR-300 were shown to increase GLP-1 and reduce DPP-4 activity during a 16-week period, supporting multiple aspects of metabolic health — all in low daily doses suitable for food, beverage and supplement applications."
The publication adds to a robust body of evidence.
More than ten human clinical studies have demonstrated that Dyglomera and CQR-300 support appetite regulation, improve body composition and enhance metabolic balance.
The new findings establish GLP-1/DPP-4 modulation as a key mechanism of action, complementing earlier research showing effects on other hormones (including leptin, adiponectin and insulin) that are central to appetite and satiety regulation.
"We now have the strongest evidence yet that these extracts support GLP-1 activity through natural pathways in the body, helping regulate appetite, reduce body fat and improve key markers of metabolic health."
"This positions Dyglomera and CQR-300 as breakthrough natural options for global weight-management and metabolic-wellness strategies," commented Dr Julius Enyong Oben, Professor of Nutritional Biochemistry at the University of Yaoundé and lead investigator.